The initial success of Sildenafil undeniably revolutionized the medication landscape, but betting in companies primarily reliant on off-patent versions presents a challenging picture. While early earnings were significant, the cessation of patents and the rise of less expensive alternatives have diminished the customer base. Thus, a thorough analys